Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus

Journal of Viral Hepatitis

Volumn 19, Issue 2, 2012, Pages

  Xiao, C ^a   Qin, B ^a   Chen, L ^b,c   Liu, H ^d   Zhu, Y ^a   Lu, X ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF BLOOD TRANSFUSION   (China)

^d Shanghai Biochip Co Ltd   (China)

Author keywords

alpha interferon; chronic hepatitis B; differential gene expression; microarray; no response to treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA1 INTERFERON; ALPHA1B INTERFERON; ASPARTATE AMINOTRANSFERASE; HECT DOMAIN AND RLD 5 PROTEIN; PROTEIN; RNA; UBIQUITIN SPECIFIC PEPTIDASE 18; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA MICROARRAY; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC SCREENING; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LIVER BIOPSY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LIVER; MALE; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME;

EID: 84855823399     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01471.x     Document Type: Article

References (39)

1. Safioleas M, Lygidakis NJ, Manti C,. Hepatitis B today. Hepatogastroenterology 2007; 54 (74): 545-548. (Pubitemid 46724727)
2. Yang YF, Zhao W, Xia HM, et al. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Antiviral Res 2010; 85 (2): 361-365.
3. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH,. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 2007; 81 (1): 159-165. (Pubitemid 44975156)
4. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56 (5): 699-705. (Pubitemid 46662938)
5. Tangkijvanich P, Komolmit P, Mahachai V, et al. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res 2010; 40 (4): 269-277.
6. Sun WJ, Qin Bo,. The Study Progress in the mechanisms of chronic hepatitis B patients no response with interferon alpha treatment. Zhonghua Nei Ke Za Zhi 2009; 48 (3): 250-252 (in chinese).
7. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137 (6): 2002-2009.
8. Han YN, Yang JL, Zheng SG, Tang Q, Zhu W,. Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients. World J Gastroenterol 2005; 11 (36): 5721-5724. (Pubitemid 41684933)
9. Gong QM, Kong XF, Yang ZT, et al. Association study of IFNR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. J Viral Hepat 2009; 16 (9): 674-680.
10. Hayashi K, Katano Y, Honda T, et al. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med Virol 2009; 81 (3): 459-466.
11. Wang X, Yuan ZH, Zheng LJ, et al. Gene expression profiles in an hepatitis B virus transfected hepatoblastoma cell line and differentially regulated gene expression by interferon-α. World J Gastroenterol 2004; 10 (12): 1740-1745. (Pubitemid 38931196)
12. Xiong W, Wang X, Liu XY, et al. Analysis of gene expression in hepatitis B virus transfected cell line induced by interferon. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2003; 35 (12): 1053-1060 (in chinese). (Pubitemid 38368293)
13. Chen PJ, Lin CG, Lin FY, Chen E, Wu LS,. Genetic structural differences between responders and non-responders to interferon therapy for chronic hepatitis-B patients. J Hum Genet 2006; 51 (11): 984-991. (Pubitemid 44800744)
14. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128 (5): 1437-1444. (Pubitemid 40712193)
15. Randall G, Chen L, Panis M, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131 (5): 1584-1591. (Pubitemid 44708944)
16. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 (3): 263-283.
17. Wright GW, Simon RM,. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003; 19 (18): 2448-2455. (Pubitemid 38016644)
18. Eisen MB, Spellman PT, Brown PO, Botstein D,. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95 (25): 14863-14868. (Pubitemid 29003722)
19. Ji X, Cheung R, Cooper S, et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003; 37 (3): 610-621. (Pubitemid 36258783)
20. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57 (4): 516-524.
21. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46 (5): 1548-1563. (Pubitemid 350155537)
22. Malakhova OA, Yan M, Malakhov MP, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 2003; 17 (4): 455-460. (Pubitemid 36258760)
23. Knobeloch KP, Utermöhlen O, Kisser A, Prinz M, Horak I,. Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol Cell Biol 2005; 25 (24): 11030-11034. (Pubitemid 41747144)
24. Osiak A, Utermöhlen O, Niendorf S, Horak I, Knobeloch KP,. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol 2005; 25 (15): 6338-6345. (Pubitemid 41023211)
25. Malakhova OA, Kim KI, Luo JK, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25 (11): 2358-2367. (Pubitemid 44012219)
26. Kim KI, Yan M, Malakhova O, et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 2006; 26 (2): 472-479. (Pubitemid 43089760)
27. Kim JH, Luo JK, Zhang DE,. The Level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol 2008; 181 (9): 6467-6472.
28. Zhou A, Paranjape JM, Der SD, Williams BR, Silverman RH,. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999; 258 (2): 435-440. (Pubitemid 29390253)
29. Presti RM, Popkin DL, Connick M, Paetzold S, Virgin HW IV,. Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages. J Exp Med 2001; 193 (4): 483-496. (Pubitemid 32524479)
30. Rang A, Bruns M, Heise T, Will H,. Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and is independent of MxA. J Biol Chem 2002; 277 (10): 7645-7647. (Pubitemid 34968208)
31. Chang JH, Kato N, Muroyama R, et al. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment. Liver Int 2010; 30 (2): 311-318.
32. Guidotti LG, Morris A, Mendez H, et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002; 76 (6): 2617-2621. (Pubitemid 34184846)
33. Kanazawa N, Kurosaki M, Sakamoto N, et al. Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol 2004; 78 (18): 9713-9720. (Pubitemid 39187089)
34. Itsui Y, Sakamoto N, Kakinuma S, et al. Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 2009; 50 (6): 1727-1737.
35. Itsui Y, Sakamoto N, Kurosaki M, et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat 2006; 13 (10): 690-700. (Pubitemid 44401198)
36. Nguyen LH, Espert L, Mechti N, Wilson III DM,. The human interferon- and estrogen-regulated ISG20/HEM45 gene product degrades single-stranded RNA and DNA in vitro. Biochemistry 2001; 40 (24): 7174-7179. (Pubitemid 32554041)
37. Espert L, Degols G, Gongora C, et al. ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses. J Biol Chem 2003; 278 (18): 16151-16158. (Pubitemid 36799737)
38. Wieland S, Thimme R, Purcell RH, Chisari FV,. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101 (17): 6669-6674. (Pubitemid 38586032)
39. Hao Y, Yang D,. Cloning, eukaryotic expression of human ISG20 and preliminary study on the effect of its anti-HBV. J Huazhong Univ Sci Technolog Med Sci 2008; 28 (1): 11-13.